Takeda, Daiichi Report Strong 9-Month Profit Increases
This article was originally published in PharmAsia News
Japan's biggest drug maker reported a 24.5 percent profit increase for the first nine months of its current business year, mainly because of its Actos (pioglitazone hydrochloride) diabetes drug. Takeda Pharmaceutical apparently benefited from safety concerns raised with GlaxoSmithKline's rival drug Avandia (rosiglitazone maleate) by a U.S. study last May. Daiichi Sankyo reported a 24 percent profit for the April-December period because of its high blood pressure treatment Benicar (hydrochlorothiazide). (Click here for more
You may also be interested in...
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.